October 9, 2024 – CanSino Biologics Inc (“CanSinoBIO” or “the Company”) is pleased to announce further  funding from the Bill & Melinda Gates Foundation (“the foundation”), receiving an over US$17 million grant to further advance its recombinant poliovirus vaccine ( “VLP-Polio”) project. This latest round of support also extends to possible related combined vaccine candidates. It builds on the initial grant received in October 2023.

Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, expressed his gratitude for the continued support, stating, “We are deeply honored by the foundation’s ongoing trust and support. This recognition not only supports our innovation and production capabilities but also advances our commitment to improving global public health. We believe our innovative VLP-Polio vaccine will play a crucial role in the worldwide effort to eradicate polio.”

The VLP-Polio vaccine, developed based on the Company’s expertise in protein structure design and VLP assembly technology platform, is a non-infectious vaccine that does not rely on live viruses. This innovative approach may result in a superior safety profile with equivalent or better immunogenicity, earning a recommendation from the World Health Organization (“WHO”) as a key tool in the future eradication of polio, especially for the post-eradication era. The vaccine candidate is positioned to be of great significance in the global efforts to control and eliminate polio, protecting millions of children and families from this devastating disease.

The Company has been actively involved in the WHO’s polio eradication strategy, closely monitoring global disease prevention needs. Funding from the foundation will further enhance CanSinoBIO’s ability to provide innovative, high-quality, and affordable vaccine worldwide, supporting the goal of making advanced vaccine products available to all.

CanSinoBIO looks forward to continuing its collaboration with global partners to address the challenges posed by infectious diseases, fulfilling its social and international responsibilities, and contributing to the advancement of global public health.

About CanSinoBIO

Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to providing high-quality, innovative, and affordable vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a rich portfolio of a pipeline products preventing more than 10 diseases, including Aisa's first vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia^® approved in over 10 countries and granted EUL by the WHO, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia^® and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia^® approved by NMPA in China. The world's first inhaled COVID-19 vaccine Convidecia Air^® has been approved as a booster dose in China, Morocco, and Indonesia. Additional information can be found online at www.cansinotech.com.